TREKSTOR
With the end of the pandemic not in sight yet, TREKSTOR is announcing the expansion of its mask portfolio, therefore fulfilling the increased demand created by regulations and customers alike.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201216005568/en/
Some of the new entries are comprised of so-called filtering half-masks, commonly known as FFP2 and FFP3. The FFP2 masks with the model name BL-03N (item 30604) are packaged 2pcs per bag with the user manual directly printed on the outside. Comprised of 5 layers, the respirators have been type-approved by notified body SGS Fimko (0598) and are valid to use for 24 months from production. They are worn with ear-straps and come with a flexible nose guard included in the fabric.
Additionally, newly available are 20pcs boxes of two FFP3 masks with the model names LT-2020AP3 (item 30613) and LT-2020AP3V (item 30614), the later which includes a vent. Both masks are foldable, also include a nose-guard and are worn with elastic headbands, that can be adjusted to fit perfectly. Like all FFP3 masks, they filter ≥99% of particles, as has been confirmed by the notified body Applus (0370). This allows them to also be used in direct contact with COVID-19 positive patients.
„The demand for filtering half-masks has increased drastically over the last few weeks“ , says Shimon Szmigiel, CEO of TREKSTOR. „Therefore, we decided to expand our portfolio beyond the already available KN95 respirators with CE approval based on EU guideline PPE-R 02.075.“
At the same time the face mask portfolio was updated. While the focus always has been on EN 14683:2019 certified masks of both types IIR and I, they were always only available for adults. But now TREKSTOR also offers type IIR face masks for children as well.
„Type IIR face masks filter ≥98% of exhaled air, therefore offering good protection for everyone around“ , Simon Wiedemann, Head of Product Management explains. „With infections spreading in schools and day care centres more and more, wearing such masks consistently can help stop the spread of the virus dramatically.“
So kids can enjoy wearing a mask, TREKSTOR decided to offer them in 10 different designs, 5 each suited for boys and girls. Each design is packed 5pcs per re-sealable bag, if kids like to be surprised, the masks are also available in 5pcs mix packs with one mask of each design present within.
The kids masks are already in stock and can be ordered online at www.blnk-healthcare.com . The shop is also ready to accept pre-orders to FFP2 and FFP3 masks, which will then be fulfilled in early January. Interested parties can also declare their interest by sending an email to sales@blnk-healthcare.com . PR requests should be directed to pr@blnk-healthcare.com .
About TREKSTOR / blnk Healthcare
TREKSTOR, known as one of Europe’s leading consumer electronics manufacturers based in Bensheim, Germany, has been active in the healthcare space with its brand blnk starting March 2020, helping to stop the spread of the virus via face masks, disinfectants and other protective equipment. The company is selling equally to government institutions and the army alongside direct sales to care facilities, hospitals, pharmacies and end-consumers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201216005568/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom